The Lynx Group

How MSI and TMB Factor into Current Biomarker Testing Panels

Videos

Featuring:

Sanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Hospital and Temple University
Philadelphia, PA

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: